SpectraCure will sponsor a North American multicenter phase l/ll/III – study for recurrent prostate cancer in 2012-2014. The first chosen indication is partly because the lack of suitable treatments for a large patient group; men previously treated for prostate cancer who has relapsed.

SpectraCure is also involved as co-sponsor in a phase I study on pancreatic cancer in London.

Spectracure is planning to conduct non-clinical studies in the area of E/N/T (Ear/ Nose / Throat).